{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,24]],"date-time":"2026-02-24T00:06:33Z","timestamp":1771891593979,"version":"3.50.1"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,5,31]],"date-time":"2022-05-31T00:00:00Z","timestamp":1653955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,5,31]],"date-time":"2022-05-31T00:00:00Z","timestamp":1653955200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Nephrol"],"published-print":{"date-parts":[[2022,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Dialysis patients and immunosuppressed renal patients are at increased risk of COVID-19 and were excluded from vaccine trials. We conducted a prospective multicentre study to assess SARS-CoV-2 vaccine antibody responses in dialysis patients and renal transplant recipients, and patients receiving immunosuppression for autoimmune disease.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Patients were recruited from three UK centres (ethics:20\/EM\/0180) and compared to healthy controls (ethics:17\/EE\/0025). SARS-CoV-2 IgG antibodies to spike protein were measured using a multiplex Luminex assay, after first and second doses of Pfizer BioNTech BNT162b2(Pfizer) or Oxford-AstraZeneca ChAdOx1nCoV-19(AZ) vaccine.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Six hundred ninety-two patients were included (260 dialysis, 209 transplant, 223 autoimmune disease (prior rituximab 128(57%)) and 144 healthy controls. 299(43%) patients received Pfizer vaccine and 379(55%) received AZ. Following two vaccine doses, positive responses occurred in 96% dialysis, 52% transplant, 70% autoimmune patients and 100% of healthy controls. In dialysis patients, higher antibody responses were observed with the Pfizer vaccination. Predictors of poor antibody response were triple immunosuppression (adjusted odds ratio [aOR]0.016;95%CI0.002\u20130.13;<jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001) and mycophenolate mofetil (MMF) (aOR0.2;95%CI 0.1\u20130.42;<jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001) in transplant patients; rituximab within 12\u2009months in autoimmune patients (aOR0.29;95%CI 0.008\u20130.096;<jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001) and patients receiving immunosuppression with eGFR 15-29\u2009ml\/min (aOR0.031;95%CI 0.11\u20130.84;<jats:italic>p<\/jats:italic>\u2009=\u20090.021). Lower antibody responses were associated with a higher chance of a breakthrough infection.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Amongst dialysis, kidney transplant and autoimmune populations SARS-CoV-2 vaccine antibody responses are reduced compared to healthy controls. A reduced response to vaccination was associated with rituximab, MMF, triple immunosuppression CKD stage 4. Vaccine responses increased after the second dose, suggesting low-responder groups should be prioritised for repeated vaccination. Greater antibody responses were observed with the mRNA Pfizer vaccine compared to adenovirus AZ vaccine in dialysis patients suggesting that Pfizer SARS-CoV-2 vaccine should be the preferred vaccine choice in this sub-group.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12882-022-02792-w","type":"journal-article","created":{"date-parts":[[2022,5,31]],"date-time":"2022-05-31T15:05:18Z","timestamp":1654009518000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["SARS-COV-2 vaccine responses in renal patient populations"],"prefix":"10.1186","volume":"23","author":[{"given":"Rona M.","family":"Smith","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel J.","family":"Cooper","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rainer","family":"Doffinger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hannah","family":"Stacey","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Abdulrahman","family":"Al-Mohammad","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ian","family":"Goodfellow","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephen","family":"Baker","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sara","family":"Lear","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Myra","family":"Hosmilo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicholas","family":"Pritchard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicholas","family":"Torpey","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Jayne","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vivien","family":"Yiu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anil","family":"Chalisey","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jacinta","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Enric","family":"Vilnar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chee Kay","family":"Cheung","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rachel B.","family":"Jones","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,5,31]]},"reference":[{"key":"2792_CR1","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1038\/s41586-020-2521-4","volume":"584","author":"EJ Williamson","year":"2020","unstructured":"Williamson EJ, Walker AJ, Bhaskaran K, et al. Factors associated with COVID-19-related death using OpenSAFELY. Nature. 2020;584:430\u20136.","journal-title":"Nature"},{"issue":"27","key":"2792_CR2","doi-asserted-by":"publisher","first-page":"2603","DOI":"10.1056\/NEJMoa2034577","volume":"383","author":"FP Polack","year":"2020","unstructured":"Polack FP, et al. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. N Engl J Med. 2020;383(27):2603\u201315. https:\/\/doi.org\/10.1056\/NEJMoa2034577 Epub 2020 Dec 10. PMID: 33301246; PMCID: PMC7745181.","journal-title":"N Engl J Med"},{"key":"2792_CR3","doi-asserted-by":"publisher","unstructured":"Baden, LR. et al. Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. N Engl J Med. 2021 384(5):403\u2013416. doi: https:\/\/doi.org\/10.1056\/NEJMoa2035389. Epub 2020 Dec 30. PMID: 33378609; PMCID: PMC7787219.","DOI":"10.1056\/NEJMoa2035389"},{"key":"2792_CR4","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1053\/j.ajkd.2019.06.014","volume":"75","author":"KM Krueger","year":"2020","unstructured":"Krueger KM, Ison MG, Ghossein C. Practical guide to vaccination in all stages of CKD, including patients treated by Dialysis or kidney transplantation. Am J Kidney Dis. 2020;75:417\u201325. https:\/\/doi.org\/10.1053\/j.ajkd.2019.06.014.","journal-title":"Am J Kidney Dis"},{"key":"2792_CR5","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1002\/art.25034","volume":"62","author":"CO Bingham 3rd","year":"2010","unstructured":"Bingham CO 3rd, et al. Immunization responses in rheumatoid arthritis patients treated with rituximab: results from a controlled clinical trial. Arthritis Rheum. 2010;62:64\u201374. https:\/\/doi.org\/10.1002\/art.25034.","journal-title":"Arthritis Rheum"},{"key":"2792_CR6","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1002\/art.25033","volume":"62","author":"S van Assen","year":"2010","unstructured":"van Assen S, et al. Humoral responses after influenza vaccination are severely reduced in patients with rheumatoid arthritis treated with rituximab. Arthritis Rheum. 2010;62:75\u201381. https:\/\/doi.org\/10.1002\/art.25033.","journal-title":"Arthritis Rheum"},{"key":"2792_CR7","doi-asserted-by":"publisher","unstructured":"Stumpf J, et al. Humoral and cellular immunity to SARS-CoV-2 vaccination in renal transplant versus dialysis patients: a prospective, multicenter observational study using mRNA-1273 or BNT162b2 mRNA vaccine. Lancet Reg Health Eur. 2021:100178. https:\/\/doi.org\/10.1016\/j.lanepe.2021.100178 Epub ahead of print. PMID: 34318288; PMCID: PMC8299287.","DOI":"10.1016\/j.lanepe.2021.100178"},{"issue":"9","key":"2792_CR8","doi-asserted-by":"publisher","first-page":"2292","DOI":"10.1016\/j.ekir.2021.06.027","volume":"6","author":"EJ Carr","year":"2021","unstructured":"Carr EJ, et al. Review of early immune responseto SARS CoV-2 vaccination among patients with CKD. Kidney Int Rep. 2021;6(9):2292\u2013304.","journal-title":"Kidney Int Rep"},{"key":"2792_CR9","doi-asserted-by":"publisher","unstructured":"Carr EJ, et al. Neutralising antibodies after COVID-19 vaccination in UK haemodialysis patients. Lancet. 2021. https:\/\/doi.org\/10.1016\/S0140-6736(21)01854-7 Epub ahead of print. Erratum in: Lancet. 2021 Aug 17;: PMID: 34391504; PMCID: PMC8360704.","DOI":"10.1016\/S0140-6736(21)01854-7"},{"issue":"21","key":"2792_CR10","doi-asserted-by":"publisher","first-page":"2204","DOI":"10.1001\/jama.2021.7489","volume":"325","author":"BJ Boyarsky","year":"2021","unstructured":"Boyarsky BJ, et al. Antibody response to 2-dose SARS-CoV-2 mRNA vaccine series in solid organ transplant recipients. JAMA. 2021;325(21):2204\u20136. https:\/\/doi.org\/10.1001\/jama.2021.7489 PMID: 33950155; PMCID: PMC8100911.","journal-title":"JAMA."},{"key":"2792_CR11","doi-asserted-by":"publisher","unstructured":"Prendecki M, et al. Comparison of humoral and cellular responses in kidney transplant recipients receiving BNT162b2 and ChAdOx1 SARS-CoV-2 vaccines. MedRxiv. https:\/\/doi.org\/10.1101\/2021.07.09.21260192.","DOI":"10.1101\/2021.07.09.21260192"},{"key":"2792_CR12","unstructured":"Kearns, P. et al. Examining the immunological effects of COVID-19 vaccination in patients with conditions potentially leading to diminished immune response capacity \u2013 the OCTAVE Trial."},{"key":"2792_CR13","doi-asserted-by":"publisher","unstructured":"Spiera R, Jinich S, Jannat-Khah D. Rituximab, but not other antirheumatic therapies, is associated with impaired serological response to SARS- CoV-2 vaccination in patients with rheumatic diseases. Ann Rheum Dis. 2021. https:\/\/doi.org\/10.1136\/annrheumdis-2021-220604 Epub ahead of print. PMID: 33975857.","DOI":"10.1136\/annrheumdis-2021-220604"},{"key":"2792_CR14","doi-asserted-by":"publisher","DOI":"10.1101\/2021.04.05.21254656","volume-title":"Glucocorticoids and B cell depleting agents substantially impair immunogenicity of mRNA vaccines to SARS-CoV-2. medRxiv [preprint]","author":"P Deepak","year":"2021","unstructured":"Deepak P, et al. Glucocorticoids and B cell depleting agents substantially impair immunogenicity of mRNA vaccines to SARS-CoV-2. medRxiv [preprint]; 2021. https:\/\/doi.org\/10.1101\/2021.04.05.21254656. PMID: 33851176; PMCID: PMC8043473"},{"issue":"9","key":"2792_CR15","doi-asserted-by":"publisher","first-page":"e627","DOI":"10.1016\/S2665-9913(21)00212-5","volume":"3","author":"SK Mahil","year":"2021","unstructured":"Mahil SK, et al. The effect of methotrexate and targeted immunosuppression on humoral and cellular immune responses to the COVID-19 vaccine BNT162b2: a cohort study. Lancet Rheumatol. 2021;3(9):e627\u201337. https:\/\/doi.org\/10.1016\/S2665-9913(21)00212-5 Epub 2021 Jul 8. PMID: 34258590; PMCID: PMC8266273.","journal-title":"Lancet Rheumatol"},{"key":"2792_CR16","doi-asserted-by":"publisher","unstructured":"Moor MB, Suter-Riniker F, Horn MP, Aeberli D, Amsler J, M\u00f6ller B, et al. Humoral and cellular responses to mRNA vaccines against SARS-CoV-2 in patients with a history of CD20 B-cell-depleting therapy (RituxiVac): an investigator-initiated, single-centre, open-label study. Lancet Rheumatol. 2021;3(11):e789-e797. https:\/\/doi.org\/10.1016\/S2665-9913(21)00251-4. Epub 2021 Sep 7.","DOI":"10.1016\/S2665-9913(21)00251-4"},{"key":"2792_CR17","doi-asserted-by":"publisher","unstructured":"Baxendale HE, et al. Critical care workers have lower seroprevalence of SARS-CoV-2 IgG compared with non-patient facing staff in first wave of COVID19. medRxiv. 2020. https:\/\/doi.org\/10.1101\/2020.11.12.20145318.","DOI":"10.1101\/2020.11.12.20145318"},{"key":"2792_CR18","doi-asserted-by":"publisher","first-page":"934","DOI":"10.1038\/s41594-020-0478-5","volume":"27","author":"X Xiong","year":"2020","unstructured":"Xiong X, et al. A thermostable, closed SARS-CoV-2 spike protein trimer. Nat Struct Mol Biol. 2020;27:934\u201341. https:\/\/doi.org\/10.1038\/s41594-020-0478-5.","journal-title":"Nat Struct Mol Biol"},{"issue":"8","key":"2792_CR19","doi-asserted-by":"publisher","first-page":"1143","DOI":"10.1136\/annrheumdis-2017-212878","volume":"77","author":"P Charles","year":"2018","unstructured":"Charles P, Terrier B, Perrodeau \u00c9, et al. French Vasculitis study group. Comparison of individually tailored versus fixed-schedule rituximab regimen to maintain ANCA-associated vasculitis remission: results of a multicentre, randomised controlled, phase III trial (MAINRITSAN2). Ann Rheum Dis. 2018;77(8):1143\u20139.","journal-title":"Ann Rheum Dis"},{"issue":"19","key":"2792_CR20","doi-asserted-by":"publisher","first-page":"1771","DOI":"10.1056\/NEJMoa1404231","volume":"371","author":"L Guillevin","year":"2014","unstructured":"Guillevin L, Pagnoux C, Karras A, et al. French Vasculitis study group. Rituximab versus azathioprine for maintenance in ANCA-associated vasculitis. N Engl J Med. 2014;371(19):1771\u201380.","journal-title":"N Engl J Med"}],"container-title":["BMC Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12882-022-02792-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12882-022-02792-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12882-022-02792-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,31]],"date-time":"2022-05-31T15:15:24Z","timestamp":1654010124000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcnephrol.biomedcentral.com\/articles\/10.1186\/s12882-022-02792-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5,31]]},"references-count":20,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["2792"],"URL":"https:\/\/doi.org\/10.1186\/s12882-022-02792-w","relation":{},"ISSN":["1471-2369"],"issn-type":[{"value":"1471-2369","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,5,31]]},"assertion":[{"value":"24 December 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 April 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 May 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All methods were carried out in accordance with relevant guidelines and regulations.All experimental protocols were approved:\u00a0\u00a01. The prospective observational cohort study (ethics reference: 20\/EM\/0180) by East Midlands - Leicester Central Research Ethics Committee.\u00a0\u00a02. Healthy controls (ethics reference: 17\/EE\/0025) by East of England - Cambridge Central Research Ethics Committee.Informed consent was obtained from all subjects.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"RM Smith has received research grants from Union Therapeutics, GlaxoSmithKline, LifeArc, Kidney Research UK and Addenbrooke\u2019s Charitable Trust. IG has received charitable research grants from the Wellcome Trust and UKRI. SL has received a charitable research grant from Addenbrookes Charitable Trust. DRW Jayne\u2019s disclosures of commercial conflicts for companies are: Astra-Zeneca, Aurinia, BMS, Boehringer-Ingelheim, GSK, Janssen, Novartis, Roche\/Genentech, Takeda & Vifor. CK Cheung has received a research grant from GlaxoSmithKline and advisory board fees from Vifor Pharma. RB Jones has received research grants from GlaxoSmithKline and Roche and advisory board fees from Vifor Pharma and GlaxoSmithKline. Rest of the authors have no Conflict of interest to declare.The results presented in this paper have not been published previously in whole or part, except in abstract format.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"199"}}